ANIP: ANI Pharmaceuticals, Inc. Stock

by  •  • Comments Off on ANIP: ANI Pharmaceuticals, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1,133.02
Enterprise Value ($M) 1,638.25
Book Value ($M) 430.80
Book Value / Share 22.06
Price / Book 2.63
NCAV ($M) -335.28
NCAV / Share -17.17
Price / NCAV -3.38

Profitability (mra)
Return on Invested Capital (ROIC) -0.01
Return on Assets (ROA) -0.01
Return on Equity (ROE) -0.02

Liquidity (mrq)
Quick Ratio 1.97
Current Ratio 2.74

Balance Sheet (mrq) ($M)
Current Assets 521.30
Assets 1,287.38
Liabilities 856.58
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a
Earnings Per Share Diluted n/a
Earnings Per Share Basic n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
01-21 13G Millennium Management Llc
11-13 13G/A Rubric Capital Management LP 0.27 -94.96
03-14 13D/A Meridian Venture Partners II GP, L.P. 6.90 -13.88
02-13 13G Vanguard Group Inc 6.31
2024-01-23 13G/A BlackRock, Inc. 12.40 27.30
2024-01-17 13D/A Esjay LLC 4.80 -4.83

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 o TRANSITION REPORT UNDER SECTION
2024-08-06 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 o TRANSITION REPORT UNDER SECTION 13 OR
2024-05-10 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q x QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 o TRANSITION REPORT UNDER SECTION 13 O
2024-02-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-02-04 45,662 173,402 26.33
2025-02-03 18,725 87,827 21.32
2025-01-31 12,382 77,665 15.94
2025-01-30 23,676 83,978 28.19

(click for more detail)

Similar Companies
ADMA – ADMA Biologics, Inc. AFMD – Affimed N.V.
ALT – Altimmune, Inc. APGE – Apogee Therapeutics, Inc.
APLT – Applied Therapeutics, Inc.


Financial data and stock pages provided by
Fintel.io